Trimethoprim(TMP) antibody/antigen (BSA/OVA/KLH conjugated hapten)
anti-Trimethoprim(TMP) antibody and Carrier-coupled antigen/immunogen (hapten-carrier conjugates)
Go to Antibiotics diagnostics products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-SMT-73-1 | 1. BSA-Trimethoprim(TMP) 2. Anti-Trimethoprim(TMP) mouse monoclonal antibody |
$2709.00 |
GMP-SMT-73-2 | 1. OVA-Trimethoprim(TMP) 2. Anti-Trimethoprim(TMP) mouse monoclonal antibody |
$2709.00 |
GMP-SMT-73-3 | 1. BSA-Trimethoprim(TMP) 2. Anti-Trimethoprim(TMP) human monoclonal antibody |
$2709.00 |
GMP-SMT-73-4 | 1. OVA-Trimethoprim(TMP) 2. Anti-Trimethoprim(TMP) human monoclonal antibody |
$2709.00 |
GMP-SMT-73-Ag-1 | BSA-Trimethoprim(TMP) | $756.00 |
GMP-SMT-73-Ag-2 | OVA-Trimethoprim(TMP) | $756.00 |
GMP-SMT-73-Ab-1 | Anti-Trimethoprim(TMP) mouse monoclonal antibody | $1953.00 |
GMP-SMT-73-Ab-2 | Anti-Trimethoprim(TMP) human monoclonal antibody | $1953.00 |
Size: 1mg | 10mg | 100mg
Product Description
BSA-Trimethoprim(TMP)
Cat No. | GMP-SMT-73-Ag-1 |
Bioactivity validation | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody; |
Products description | Competitive immunoassay-validated hapten-carrier conjugates BSA-Trimethoprim(TMP) with anti-Hapten antibody. The hapten hapten-carrier conjugates BSA-Trimethoprim(TMP) had been validated with our anti-Hapten antibody Anti-Trimethoprim(TMP) mouse monoclonal antibody via competitive ELISA test. |
Application | ELISA tests and
other immunoassays; Lateral flow immunoassay (LFIA); LTIA Immunonephelometry Time-resolved Fluorescence Immunoassay (TRFIA) |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
OVA-Trimethoprim(TMP)
Cat No. | GMP-SMT-73-Ag-2 |
Bioactivity validation | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody; |
Products description | Competitive immunoassay-validated hapten-carrier conjugates OVA-Trimethoprim(TMP) with anti-Hapten antibody. The hapten hapten-carrier conjugates OVA-Trimethoprim(TMP) had been validated with our anti-Hapten antibody Anti-Trimethoprim(TMP) mouse monoclonal antibody via competitive ELISA test. |
Application | ELISA tests and
other immunoassays; Lateral flow immunoassay (LFIA); LTIA Immunonephelometry Time-resolved Fluorescence Immunoassay (TRFIA) |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Anti-Trimethoprim(TMP) mouse monoclonal antibody
Cat No. | GMP-SMT-73-Ab-1 |
Host of Antibody | Mouse IgG |
Bioactivity validation | Competitive immunoassay validation
(Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody; Lateral flow immunoassay (LFIA); |
ELISA IC50 (ppb) | 0.20 |
Products description | The anti-Hapten antibody against hapten Trimethoprim(TMP) had been validated with our hapten hapten-carrier conjugates BSA-Trimethoprim(TMP) via competitive ELISA test. |
Application | ELISA tests and
other immunoassays; Lateral flow immunoassay (LFIA); LTIA Immunonephelometry Time-resolved Fluorescence Immunoassay (TRFIA) |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Anti-Trimethoprim(TMP) human monoclonal antibody
Cat No. | GMP-SMT-73-Ab-2 |
Host of Antibody | Human IgG1 |
Bioactivity validation | Competitive immunoassay validation
(Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody; Lateral flow immunoassay (LFIA); |
ELISA IC50 (ppb) | 0.20 |
Products description | The anti-Hapten antibody against hapten Trimethoprim(TMP) had been validated with our hapten hapten-carrier conjugates BSA-Trimethoprim(TMP) via competitive ELISA test. |
Application | ELISA tests and
other immunoassays; Lateral flow immunoassay (LFIA); LTIA Immunonephelometry Time-resolved Fluorescence Immunoassay (TRFIA) |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
Trimethoprim is a synthetic derivative of trimethoxybenzyl-pyrimidine with antibacterial and
antiprotozoal properties. Sulfamethoxazole with trimethoprim is a fixed antibiotic combination
that is widely used for mild-to-moderate bacterial infections and as prophylaxis against
opportunistic infections. Recently, our R&D department demonstrated that our GMP-SMT-73-Ab-1
(Anti-Trimethoprim(TMP) mouse monoclonal antibody) has a large linear range and good sensitivity
against the GMP-SMT-73-Ag-1 (BSA-Trimethoprim(TMP)). Below is the result of GeneMedi's
Anti-Trimethoprim(TMP) mouse monoclonal antibody validation with BSA-Trimethoprim(TMP) in ELISA.
We highly recommend the Ab&Ag to you.
Figure 1. GeneMedi's GMP-SMT-73-Ab-1 (Anti-Trimethoprim(TMP) mouse monoclonal antibody)
is validated to detect the GMP-SMT-73-Ag-1 (BSA-Trimethoprim(TMP)) in ELISA. EC50 = 234.5
ng/ml.
Click to get more Data / Case study about the product.
Biomarker Information
1. Trimethoprim (TMP) Description:
1.Trimethoprim (TMP), scientifically identified as
2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine, occupies a notable position within the realm
of antimicrobial therapeutics. This synthetic antibacterial compound is classified under the
dihydrofolate reductase inhibitors, a class renowned for its efficacy in combating bacterial
infections. Here, we delve into a comprehensive understanding of TMP's chemical structure, mode
of action, and its indispensable role in veterinary pharmacology.
Chemical Structure and
Composition:
2.TMP presents a complex and intricate chemical structure. It is primarily
characterized by a pyrimidine ring, a five-membered heterocyclic ring, harboring two amino
groups at positions 2 and 4. Additionally, TMP features a benzyl ring with three methoxy (CH3O)
groups at positions 3, 4, and 5. These structural components render TMP a potent antimicrobial
agent with high specificity for its target, dihydrofolate reductase.
Mechanism of
Action:
3.TMP's therapeutic prowess hinges on its ability to interfere with the bacterial
folate synthesis pathway. Bacteria, much like their human counterparts, rely on the synthesis of
folate (a B-vitamin) for the production of DNA, RNA, and proteins, critical for their growth and
proliferation. Central to this process is the enzyme dihydrofolate reductase, which facilitates
the conversion of dihydrofolic acid into tetrahydrofolic acid, a pivotal precursor in folate
synthesis. TMP operates as a potent inhibitor of dihydrofolate reductase, disrupting the
enzymatic conversion of dihydrofolic acid to tetrahydrofolic acid. As a consequence, the
bacteria's ability to generate essential biomolecules is severely compromised, leading to
bacteriostasis—the halting of bacterial growth.
Role in Veterinary Drug Residues and
Additives (Serial Number 1):
4.Veterinary Drug Residues: TMP plays a pivotal role in the
context of veterinary drug residues, particularly in the livestock and poultry industries. It is
administered to animals as a therapeutic agent to combat bacterial infections. However, the
presence of drug residues in animal-derived products such as meat, milk, and eggs poses a
potential risk to human health. Monitoring TMP residues is, therefore, imperative to ensure the
safety and quality of these consumable products. Regulatory bodies establish maximum residue
limits (MRLs) for TMP, and exceeding these limits is a serious concern. Accurate measurement and
control of TMP levels are critical for complying with these regulations and safeguarding public
health.
5.Additives in Animal Feed: In addition to its role as a therapeutic agent, TMP
may also be employed as an additive in animal feed formulations. The inclusion of TMP in animal
diets serves a dual purpose—prevention and treatment. As a preventive measure, it helps control
bacterial infections in livestock, reducing the occurrence of diseases that can significantly
impact animal health and productivity. Furthermore, TMP in animal feed can be utilized to
enhance the overall well-being of livestock by reducing the incidence of bacterial-related
illnesses, which can be economically detrimental. By bolstering animal health, TMP contributes
to the production of safe and high-quality animal-derived products.
6.Pharmacokinetics in
Veterinary Medicine: Understanding the pharmacokinetics of TMP in veterinary medicine is
critical to its effective and safe administration. TMP is absorbed through the gastrointestinal
tract and reaches peak blood concentrations relatively quickly, making it a practical choice for
oral administration. This rapid absorption is advantageous in combatting bacterial infections
swiftly. It is then distributed throughout the body, allowing it to reach various tissues and
bodily fluids, which is particularly important in the context of systemic infections. TMP is
primarily excreted through the kidneys, which emphasizes the importance of proper dosage and
considerations for animals with impaired renal function.
2. Reasons to Measure
Trimethoprim (TMP) (Serial Number 2):
7.Ensuring Food Safety:
8.Rigorous and
systematic quantification of TMP levels in animal-derived products serves as an indispensable
facet of upholding the highest standards of food safety. The presence of TMP residues in these
products must be closely monitored to ensure that they do not exceed established regulatory
limits. This stringent surveillance not only safeguards consumer well-being but also underscores
the commitment to delivering products that meet the most rigorous safety standards. Any breaches
in these limits can have profound implications for public health, necessitating strict adherence
to these measures.
9.Compliance with Stringent Regulations:
10.In the context of
veterinary pharmacology and the use of TMP, compliance with stringent regulations is paramount.
Regulatory authorities set forth guidelines and maximum residue limits (MRLs) for TMP in
animal-derived products. These limits are established to protect consumers from potential health
risks associated with excessive drug residues. Regular monitoring and quantification of TMP
levels are, therefore, mandatory to ensure full compliance with these regulations. Such
diligence not only prevents legal repercussions but also maintains the integrity and reputation
of the biopharmaceutical company.
11.Optimizing Therapeutic Efficacy:
12.The
accurate measurement of TMP concentrations in animals undergoing treatment is instrumental in
fine-tuning therapeutic interventions. This precision allows veterinarians to tailor dosage
regimens to individual animals, ensuring that the therapeutic effects of TMP are maximized. By
avoiding underdosing, veterinarians can effectively combat bacterial infections while minimizing
the risk of antibiotic resistance, which is a growing concern in both human and veterinary
medicine.
13.Combatting Antibiotic Resistance:
14.The global emergence of
antibiotic resistance is a pressing issue in healthcare and veterinary medicine. The overuse and
misuse of antibiotics, including TMP, contribute to the development of resistant bacterial
strains. Measuring TMP levels is a proactive strategy to combat this threat. By ensuring that
TMP is used judiciously and in accordance with established guidelines, the veterinary industry
plays a vital role in mitigating antibiotic resistance. The meticulous quantification of TMP
levels supports responsible veterinary practices and aligns with the overarching objective of
preserving the effectiveness of antibiotics for future generations.
15.Quality Control in
Production:
16.For a biopharmaceutical enterprise specializing in the production of
anti-TMP antibodies and small molecules competitive antigens, meticulous TMP measurement serves
as a linchpin of quality assurance. It is paramount to ensure that these products meet rigorous
standards and specifications, as they form an integral component of veterinary diagnostic and
research applications. Consistency and accuracy in the production of these molecules are
critical, as they directly impact the reliability and effectiveness of diagnostic tests,
research studies, and immunological applications. By adhering to strict quality control measures
in the production process, the biopharmaceutical company instills confidence among consumers,
veterinarians, and researchers in the efficacy and precision of their offerings.
In
conclusion, TMP, as a dihydrofolate reductase inhibitor, holds a prominent position in
veterinary pharmacology. Its chemical structure and mechanism of action make it an effective
antimicrobial agent. Its dual role in veterinary drug residues and as an animal feed additive
underscores the importance of accurate measurement and monitoring. Ensuring food safety,
regulatory compliance, therapeutic efficacy, and responsible antibiotic use are essential
factors in the comprehensive management of TMP in veterinary medicine, and quality control in
the production of related biopharmaceutical products is paramount for reliability and trust in
the industry.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.